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Abstract
Little is known about the needs or characteristics of transgender individuals in substance abuse treatment
settings. Transgender (n = 199) and non-transgender (cisgender, n = 13,440) individuals were compared on
psychosocial factors related to treatment, health risk behaviors, medical and mental health status and
utilization, and substance use behaviors within a database that documented individuals entering substance
abuse treatment in San Francisco, CA from 2007 to 2009 using logistic and linear regression analyses (run
separately by identified gender). Transgender men (assigned birth sex of female) differed from cisgender men
across many psychosocial factors, including having more recent employment, less legal system involvement,
greater incidence of living with a substance abuser, and greater family conflict, while transgender women

(assigned birth sex of male) were less likely to have minor children than cisgender women. Transgender women
reported greater needle use, and HIV testing rates were greater among transgender women. Transgender men
and women reported higher rates of physical health problems, mental health diagnoses, and psychiatric
medications, but there were no differences in service utilization. There were no differences in substance use
behaviors except that transgender women were more likely to endorse primary methamphetamine use.
Transgender individuals evidence unique strengths and challenges that could inform targeted services in
substance abuse treatment.
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1. Introduction
Little is known about the substance use behaviors of transgender1 persons as national substance use
surveillance systems and epidemiological surveys predominantly assume that all participants are “cisgender,”
meaning that a participant's gender is congruent with the sex assigned at birth, even though transgender
individuals are estimated to comprise between 0.3 and 0.6% of the population (Conron, Scott, Stowell, &
Landers, 2012). Recent evidence from state-level health surveillance systems indicates that transgender persons,
relative to their cisgender counterparts, are at elevated risk for smoking cigarettes, although not at elevated risk
for binge drinking (Conron et al., 2012). A meta-analysis of available research indicates high rates of substance
use among transgender individuals (Herbst et al., 2008), while local needs assessment research of transgender
individuals in Washington, DC identified high rates of substance use disorders among the transgender
community (Xavier, 2000). Taken together, this suggests that transgender individuals may have a high need for
substance abuse treatment, but specific needs or profiles of transgender individuals in treatment are unknown.
Previous studies examining substance abuse treatment programs were unable to conduct meaningful
comparisons of transgender and cisgender individuals, as the transgender sample was too small (Cochran and
Cauce, 2006, Cochran et al., 2008). In sum, we know very little about substance use or substance abuse
treatment needs among the transgender population, but the limited evidence suggests that transgender
individuals may be at increased risk for substance use and correspondingly have substance abuse treatment
needs.
Meyer's minority stress theory (Meyer, 2003), originally developed to explain increased mental health and
substance use risk among lesbian, gay, and bisexual individuals, posits that members of minority groups may
experience additional stress as a result of stigma associated with their minority group membership. This model
was applied to transgender individuals (Hendricks & Testa, 2012), and suggests that increased experiences of
prejudice, expectations of experiencing prejudice, concealment of one's minority status, and internalization of
social stigma are processes that put transgender individuals at risk for poorer health, substance use, and mental
health outcomes. Research indicates that transgender individuals experience increased prejudice, in the form of
extremely high rates of physical abuse, sexual assault, employment discrimination (Herbst et al., 2008), and
harassment (Factor and Rothblum, 2008, Grant et al., 2011). Additionally, research suggests high rates of
concealment of gender identity among transgender people (Maguen, Shipherd, Harris, & Welch, 2007) in an
effort to avoid conflict, harassment and intimidation (Beemyn & Rankin, 2011). Taken together, these findings
suggest that transgender individuals may be subject to minority stress and may therefore experience increased
severity of substance use and poorer mental health and health outcomes. In line with this theory, meta-analytic
evidence estimates that transgender individuals, in particular male to female individuals (individuals assigned
birth sex of male but with an identified gender of female), are at elevated risk for HIV and sexually transmitted
disease infection (Herbst et al., 2008). Additionally, emerging evidence demonstrates that among transgender

persons, there are higher rates of non-medical use of prescription drugs among those experiencing
discrimination based on transgender identity, or mood or anxiety symptoms (Benotsch et al., 2013).
The present study advances the research by comparing characteristics of transgender and cisgender persons
entering substance abuse treatment in order to provide a profile of the transgender population on
characteristics that could influence substance abuse treatment. To our knowledge, this is the first investigation
to make such comparisons and as such our analyses are exploratory. Using existing theory and research we
anticipated that after controlling for age, ethnicity, and race, transgender individuals would endorse unique
psychosocial characteristics related to treatment including less paid work, higher legal system involvement,
higher likelihood of living with a substance user, fewer children under 17, less involvement in recovery oriented
activities, and more family conflict. In addition, based on prior research and theory it was expected that
transgender individuals would evidence increased risk for engagement in health risk behaviors and report
greater medical and mental health problems and healthcare service utilization. While exploratory in nature due
to limited available research, we anticipated that there would be differences in primary substance for which
treatment was being sought and route of administration for transgender individuals. Given that psychosocial
challenges faced by transgender men and women can differ considerably (Lev, 2004), we considered
transgender men and women separately.

2. Methods
This study used data from the County of San Francisco, and included admission records for all clients entering
publically funded substance abuse treatment services at one of up to 62 programs in the County of San
Francisco from July 2007 through December 2009 (N = 14,015). The database was compiled from the mandatory
entries of substance abuse counselors on the characteristics of their clients, obtained from clients at intake. The
County of San Francisco released a de-identified version of the database to our research team to facilitate this
research. This study was exempt from the University of California Committee on Human Research review, as it
used de-identified data.
Within the database, clients had unique identifiers to prevent the duplication of client records. For clients who
sought treatment during the specified time period, data on multiple treatment episodes within the county were
available. For each individual, the most recent treatment episode was selected for use in these analyses (from
107,470 total treatment episodes).

2.1. Measures

The database included questions from the California Outcomes Measurement System (CALOMS). CALOMS is a
California statewide data collection system that was designed to meet multiple data recording and reporting
requirements including: Treatment Episode Data Sets, California Alcohol and Drug Data Set, and National
Outcome Measures. CALOMS was implemented in 2006 to provide a consistent form of measurement across
California to evaluate substance abuse treatment programs. CALOMS queries multiple areas including: client
race, ethnicity, employment and educational status, legal system involvement (e.g., not involved with the legal
system versus on probation, parole, diversion, or awaiting trial), whether the individual lives with a substance
user, parental status, whether the individual is involved in activities supportive of recovery (such as 12-step
meetings), needle use, whether or not the individual has been tested for HIV, self reported Hepatitis C and
sexually transmitted disease status, hospital and emergency room use, whether or not the individual has a
mental health diagnosis, medication use for mental health, inpatient and emergency mental health services
used, primary drug for which the individual is seeking treatment and frequency of use, age that this substance
was first used, and mode of administration of this substance. CALOMS data are recorded upon client admission
based on client self-report. For clients who are in the same treatment program for more than one year, an
annual update may replace initial client admission information (this was done before the data was released to

the researchers). Many variables are measured over the 30 days prior to admission, treatment update, or
discharge (for example, for substance use measurement the question is “how many days in the past 30 days has
the client used the primary drug?” and when measuring mental health emergency room use, the question is
“how many times in the past 30 days has the client received outpatient emergency services for mental health
needs?”). CALOMS data has been used in multiple studies reported in peer-reviewed literature (Brecht and
Urada, 2011, Conner et al., 2011, Evans et al., 2012, Gonzales et al., 2011, Swartz, 2010). It has also undergone a
complete independent evaluation by Integrated Substance Abuse Programs at the University of California, Los
Angeles (Rawson, Gonzales, Brecht, Crèvecoeur-MacPhail, & Hemberg, 2008).
Questions querying gender identity and sexual orientation are not included in CALOMS. The County of San
Francisco added these questions to the data collection for their county's programs. Thus, gender identity and
sexual orientation data are not available at the state level, only at the county level. When reporting gender
identity, participants were offered four options: “male to female,” “female to male,” “not transgender,” and
“decline to answer.” The term female to male is used to denote an individual with an assigned birth sex of
female and identified gender of male, while the term male to female indicates an assigned birth sex of male and
identification with the female gender. For the purpose of this study, individuals who identified as male to female
were designated transgender women, while individuals who identified as female to male were designated
transgender men. Individuals who endorsed “decline to answer” when gender identity was queried could
represent both transgender individuals who do not represent a dichotomous gender identification and
individuals who do not understand the question. Thus, individuals who declined to answer the question about
gender identity are not included in this study. Participants had six options when reporting their sexual
orientation: “heterosexual,” “gay: male/male,” “lesbian: female/female,” “bisexual,” “decline to answer,” and
“unsure.”

2.2. Participants

There were 14,015 individuals with unique identifiers. Participants received services between July 2007 and
December 2009 at one or more of the substance abuse treatment programs operated or funded by the
Department of Public Health of San Francisco. Participants were included if they presented for substance abuse
treatment and have data in the database.

2.3. Analyses

All analyses were conducted separately by identified gender. Specifically, individuals who endorsed female sex
and reported they were “not transgender” (hereafter referred to as cisgender women) were compared to
individuals who endorsed “Male to female” on transgender status (hereafter referred to as transgender
women). Similarly, individuals who endorsed male sex and indicated they were “not transgender” (hereafter
referred to as cisgender men) were compared to individuals who endorsed “Female to male” gender identity
(hereafter referred to as transgender men).
Chi-square analyses were used to identify differences in race, ethnicity, and sexual orientation for transgender
and cisgender men and women; multiple regression analyses were used to identify if transgender status
predicted current age. Logistic regression analyses were used to identify differences in dichotomous variables
between cisgender and transgender men and women in substance abuse treatment at admission (full listing of
variables is in Table 2, Table 3). Multinomial regression analyses were used to predict primary substance of
abuse (“other substance” was the reference category) and route of administration for the primary substance
(“inhalation” was the reference category). Linear regression analyses used transgender status to predict
continuous outcome variables (years of education, age first used primary drug). Days of use of primary drug
prior to entering treatment was examined in a two part process. First chi-square analyses compared those who
endorsed no use versus those who endorsed 1–30 days of use. Next, those who endorsed 1 or more days of use

were retained for linear regression analyses using transgender status to predict days of use. Within all analyses
(aside from chi-square analyses) age, race, and ethnicity were selected a priori to be entered into the models as
covariates to control for their effects on the outcome variables of interest. Race and ethnicity were
dichotomized (non-White and Hispanic were entered into the models as separate covariates) to enhance the
stability of the models. Due to the large number of analyses, the alpha level was set at p = .01 to minimize type I
error. In accordance with convention, 95% confidence intervals are reported for all analyses, but only analyses
that met the more stringent p < .01 criterion were determined to have rejected the null hypothesis.

3. Results
3.1. Demographics and referral source

Complete demographic information and referral source for treatment is reported in Table 1; notable results or
results not covered in the table are reported here. The "Total" column in Table 1 reports demographic
information for the entire sample, including individuals who did not answer gender identity questions and thus
were not retained for subsequent analyses. Transgender men were younger (M = 26.92, SD = 10.79) than
cisgender men (M = 39.27, SD = 13.20, B = − 12.07, semi-partial R2 = .005, p < .001), while there were no
detectable differences between transgender and cisgender women (M = 37.78, SD = 11.78 for transgender
women, M = 35.36, SD = 13.73 for cisgender women; B = 2.49, semi-partial R2 = .001, p = .025). Notably, some
transgender individuals reported their current sex in a manner that was congruent with their sex assigned at
birth (n = 81, 40.7%), while others identified their current sex in a manner that was incongruent with their sex
assigned at birth but consistent with their current gender identity (n = 83, 41.7%). Additionally, 34 (17.1%) of the
transgender treatment-seekers identified their sex as “other.” Most of the transgender individuals (n = 115,
57.8%) reported a non-White race, and some reported a Hispanic or Latino ethnicity (n = 48, 24.1%). Among
men, transgender individuals were more likely to endorse a White race than cisgender men (non-White versus
White, X2 [1] = 7.04, p = .008) but did not differ from cisgender individuals on ethnicity (Hispanic/Latino versus
non-Hispanic/Latino, X2 [1] = 2.24, p = .135). Among women, neither race nor ethnicity differed by transgender
status (non-White versus White, X2 [1] = 2.07, p = .151; non-Hispanic/Latina versus
Hispanic/Latina, X2 [1] = 1.43, p = .231). Transgender men were far more likely to endorse non-heterosexual
sexual orientations than cisgender men (61.0% versus 10.9%, X2 [1] = 104.11, p < .001). This effect was also
observed for women, with 42.9% of transgender women reporting a non-heterosexual orientation, while only
11.6% of cisgender women reported a non-heterosexual sexual orientation (X2 [1] = 114.54, p < .001) There was
no difference between transgender and cisgender men (B = .508, semi-partial R2 < .001, p = .127) or women
(B = − .066, semi-partial R2 < .001, p = .740) in the number of years of education. Of the entire sample, 287
individuals (2 of which were transgender) had valid dates indicating that an annual update had been performed
on their treatment record, and some individuals were in treatment longer than one year without an annual
update.

Table 1. Demographic and referral source by gender and transgender status.
Total
Cisgender
Transgender
(N = 14,015)
women
women
(n = 4011)
(n = 146)
Age (M, SD)
38.31 (13.54)
35.36 (13.73)
37.78 (11.78)
Reported sex (n, %)
Male
9774 (69.7%)
n/a
72 (49.3%)
Female
4193 (29.9%)
4011 (100%)
60 (41.1%)
Other
46 (0.3%)
n/a
14 (9.6%)
Unknown
2 (0.01%)
n/a
0 (0.0%)
Race (n, %)
White
5039 (36.0%)
1284 (32.0%)
55 (37.7%)
Black
5069 (36.2%)
1558 (38.8%)
39 (26.7%)
Native American/Alaska
186 (1.3%)
74 (1.8%)
4 (2.7%)
native
Asian American/Pacific
771 (5.5%)
201 (5.0%)
5 (3.4%)
Islander
Multi racial
722 (5.2%)
282 (7.0%)
14 (9.6%)
Other race
2227 (15.9%)
612 (15.3%)
29 (19.9%)
Ethnicity(n, %)
Not Hispanic
11,388 (81.3%)
3237 (80.7%)
112 (76.7%)
Mexican/Mexican American
1134 (8.1%)
336 (8.4%)
12 (8.2%)
Cuban
68 (0.5%)
9 (0.2%)
4 (2.7%)
Puerto Rican
197 (1.4%)
73 (1.8%)
5 (3.4%)
Other Hispanic/Latino
1228 (8.8%)
356 (8.9%)
13 (8.9%)
Sexual orientation(n, %)
Heterosexual
11,984 (85.5%)
3452 (86.1%)
76 (52.1%)
Gay male/male
868 (6.2%)
22 (0.5%)
31 (21.2%)
Lesbian female/female
173 (1.2%)
156 (3.9%)
8 (5.5%)
Bisexual
523 (3.7%)
273 (6.8%)
18 (12.3%)
Decline to answer
238 (1.7%)
72 (1.8%)
4 (2.7%)
Unsure
95 (0.7%)
36 (0.9%)
9 (6.2%)
Mean years of education (M,
11.92 (2.54)
11.69 (2.54)
11.77 (2.63)
SD)
Referral source(n, %)
Self
3239 (26.6%)
1185 (33.2%)
46 (35.9%)

Comparisons
among
women
p = .025

p = .151a

p = .231a

p < .001a

p = .740

Cisgender
men
(n = 9429)
39.27 (13.20)

Transgender
men (n = 53)

Comparisons
among men

26.92 (10.79)

p < .001

9429 (100%)
n/a
n/a
n/a

23 (43.4%)
9 (17.0%)
20 (37.7%)
1 (1.9%)

3494 (37.1%)
3344 (35.5%)
104 (1.1%)

29 (54.7%)
6 (11.3%)
0 (0.0%)

549 (5.8%)

1 (1.9%)

411 (4.4%)
1526 (16.2%)

8 (15.1%)
9 (17.0%)

7692 (81.6%)
749 (7.9%)
52 (0.6%)
117 (1.2%)
819 (8.7%)

39 (73.6%)
5 (9.4%)
1 (1.9%)
0 (0.0%)
8 (15.1%)

8318 (88.2%)
797 (8.5%)
1 (< 0.1%)
215 (2.3%)
62 (0.7%)
36 (0.4%)
12.02 (2.52)

16 (30.2%)
12 (22.6%)
4 (7.5%)
9 (17.0%)
9 (17.0%)
3 (5.7%)
12.19 (3.14)

1835 (22.8%)

19 (36.5%)

p = .008a

p = .135a

p < .001a

p = .127

Family or friend
501 (4.1%)
222 (6.2%)
7 (5.5%)
262 (3.2%)
4 (7.7%)
Other substance abuse
3599 (29.6%)
707 (19.8%)
20 (15.6%)
2782 (34.5%) 2 (3.8%)
treatment
Court or criminal justice
1535 (12.6%)
330 (9.2%)
8 (6.3%)
1169 (14.5%) 3 (5.8%)
Health, social, community
2413 (19.8%)
759 (21.2%)
40 (31.3%)
1536 (19.0%) 18 (34.6%)
service
Employer or school
544 (4.5%)
235 (6.6%)
3 (2.3%)
294 (3.6%)
3 (5.8%)
Other
330 (2.7%)
134 (3.8%)
4 (3.1%)
186 (2.3%)
3 (5.8%)
a
Comparisons of race, ethnicity, and sexual orientation were dichotomized (i.e., White vs. non-White, Hispanic/Latino vs. non-Hispanic/Latino, and
heterosexual vs. non-heterosexual).

3.2. Psychosocial factors related to treatment

Complete results of logistic and multinomial regression analyses are documented in Table 2, Table 3.
Transgender men differed from cisgender men on many psychosocial factors; they were more likely to have
been paid for work in the previous 30 days, less likely to have been involved with the legal system (e.g., less
likely to be on parole, probation, awaiting trial, or on diversion), more likely to be living with a substance user in
the previous 30 days, and more likely to have experienced family conflict in the 30 days prior to treatment.
Among women, transgender individuals were less likely to have children under the age of 17, but there were no
differences on any of the other psychosocial variables.
Table 2. Logistic regression comparing cisgender (reference group) and transgender women entering substance
abuse treatment: adjusted for age, race, and ethnicity.
Cisgender n (%) Transgender
Adj. OR 95% CI
n (%)
Psychosocial factors
Paid work in past 30 days
444 (11.5%)
10 (6.9%)
0.56
0.29, 1.07
Involved with legal system
1184 (29%)
51 (34.9%)
1.35
0.95, 1.92
Living with substance user in past 30 days
462 (12.0%)
24 (16.6%)
1.42
0.90, 2.23
Children under 17
1351 (33.7%)
9 (6.2%)
0.07, 0.25
0.13⁎⁎
Involved in recovery oriented activities in past
808 (20.8%)
40 (27.6%)
1.36
0.94, 1.99
30 days
Family conflict in past 30 days
526 (13.8%)
18 (12.4%)
0.93
0.56, 1.56
Health risk behaviors
Used needles in past year
1106 (30.8%)
60 (43.8%)
1.18, 2.43
1.70⁎
Diagnosed with Hepatitis C
378 (9.7%)
13 (9.0%)
0.80
0.44, 1.45
Diagnosed with any sexually transmitted disease 86 (2.2%)
6 (4.1%)
1.79
0.77, 4.18
Tested for HIV
2671 (71.4%)
127 (88.2%)
1.67, 4.81
2.83⁎⁎
Medical and mental health service utilization
ER visit in last 30 days
415 (10.7%)
24 (16.6%)
1.52
0.96, 2.39
Hospital overnight for medical in past 30 days
203 (5.2%)
11 (7.6%)
1.36
0.72, 2.58
Physical health problems past 30 days
933 (24.1%)
52 (35.9%)
1.14, 2.34
1.64⁎
Outpatient emergency mental health care past
121 (3.1%)
6 (4.1%)
1.24
0.53, 2.87
30 days
Hospital or psychiatric facility for mental health
145 (3.7%)
8 (5.5%)
1.42
0.68, 2.95
in past 30 days
Prescribed medication for mental health in past 897 (23.1%)
59 (40.7%)
1.50, 3.03
2.13⁎⁎
30 daysa
Ever diagnosed with mental illnessa
1489 (40.0%)
88 (61.1%)
1.60, 3.24
2.28⁎⁎
Substance use: Primary problem
Alcohol
790 (19.7%)
29 (19.9%)
2.12
0.64, 7.03
Cocaine
817 (20.4%)
29 (19.9%)
2.21
0.66, 7.38
Heroin
1075 (26.8%)
32 (21.9%)
1.69
0.51, 5.59
Methamphetamine
395 (9.8%)
38 (26.0%)
1.84, 19.90
6.04⁎
Marijuana
369 (9.2%)
7 (4.8%)
1.85
0.46, 7.42
Other drug
182 (4.5%)
3 (2.1%)
ref
ref
Primary substance: Route of administration
Inhaled
198 (5.5%)
7 (5.1%)
ref
ref
Injection
1061 (29.7%)
46 (33.6%)
1.16
0.51, 2.62
Oral
952 (26.6%)
32 (23.4%)
0.91
0.40, 2.10

Smoking
1363 (38.1%)
52 (38.0%)
1.18
0.53, 2.64
Analyses involving mental health diagnoses and medications for mental health conditions should be interpreted
with caution, as many transgender individuals may have diagnoses of or medications for Gender Identity
Disorder per DSM-IV-TR (American Psychiatric Association, 2000).
⁎p < .01.
⁎⁎p < .001.
a

Table 3. Logistic regression comparing cisgender (reference group) and transgender men entering substance
abuse treatment: adjusted for age, race, and ethnicity.

Psychosocial factors
Paid work in past 30 days
Involved with legal system
Living with substance user in past 30 days
Have children under 17
Involved in recovery oriented activities in
past 30 days
Family conflict in past 30 days
Health risk behaviors
Used needles in past year
Diagnosed with Hepatitis C
Diagnosed with any sexually transmitted
disease
Tested for HIV
Medical and mental health service
utilization
ER visit in last 30 days
Hospital overnight for medical in past
30 days
Physical health problems past 30 days
Outpatient emergency mental health care
past 30 days
Hospital or psychiatric facility for mental
health in past 30 days
Prescribed medication for mental health in
past 30 daysa
Ever diagnosed with mental illnessa
Substance use: Primary problem
Alcohol
Cocaine
Heroin
Methamphetamine
Marijuana
Other drug
Primary substance: Route of administration
Inhaled

Cisgender n (%) Transgender n (%) Adj.
OR

95% CI

1375 (15.0%)
3775 (40.2%)
886 (9.7%)
2024 (21.5%)
1982 (21.6%)

18 (34.6%)
6 (11.3%)
21 (40.4%)
4 (7.5%)
16 (30.8%)

2.30⁎
0.14⁎⁎
5.26⁎⁎
0.31
1.84

1.29, 4.12
0.06, 0.33
2.99, 9.25
0.11, 0.86
1.01, 3.34

693 (7.6%)

17 (32.7%)

4.29⁎⁎ 2.36, 7.81

2573 (28.5%)
688 (7.5%)
180 (2.0%)

8 (19.5%)
2 (3.9%)
2 (3.9%)

0.68
1.01
2.24

0.30, 1.50
0.24, 4.26
0.53, 9.42

6411 (70.6%)

40 (78.4%)

2.28

1.15, 4.51

989 (10.8%)
500 (5.4%)

6 (11.5%)
3 (5.8%)

1.42
1.52

0.60, 3.36
0.47, 4.96

2099 (22.8%)
219 (2.4%)

17 (32.7%)
1 (1.9%)

2.38⁎
0.87

1.30, 4.33
0.12, 6.35

305 (3.3%)

4 (7.7%)

2.69

0.95, 7.59

1583 (17.2%)

19 (36.5%)

3.30⁎⁎ 1.84, 5.94

2813 (31.1%)

28 (53.8%)

2.88⁎⁎ 1.63, 5.08

2423 (25.7%)
2163 (22.9%)
2220 (23.5%)
1025 (10.9%)
916 (9.7%)
339 (3.6%)

15 (28.3%)
8 (15.1%)
8 (15.1%)
3 (5.7%)
5 (9.4%)
3 (5.7%)

0.87
0.75
0.70
0.29
0.34
ref

0.25, 3.07
0.19, 2.95
0.18, 2.70
0.06, 1.45
0.08, 1.52
ref

594 (6.6%)

2 (4.9%)

ref

ref

Injection
2315 (25.7%)
8 (19.5%)
1.28
0.27, 6.17
Oral
2750 (30.5%)
16 (39.0%)
1.73
0.40, 7.61
Smoking
3345 (37.2%)
15 (36.6%)
1.31
0.30, 5.79
a
Analyses involving mental health diagnoses and medications for mental health conditions should be interpreted
with caution, as many transgender individuals may have diagnoses of or medications for Gender Identity
Disorder per DSM-IV-TR (American Psychiatric Association, 2000).
⁎p < .01.
⁎⁎p < .001.

3.3. Health risk behaviors

Transgender women were more likely than cisgender women to have used needles in the previous year and
were more likely to have been tested for HIV. Transgender men had higher odds of being tested for HIV than
cisgender men, but not at a level that met the criterion p < .01 (AdjOR = 2.28; 95% CI = 1.15, 4.51, p = .018). There
were no detectable differences in rates of reported Hepatitis C diagnoses or sexually transmitted disease
diagnoses.

3.4. Medical and mental health status and service utilization

Both transgender men and women were more likely than cisgender men and women to report experiencing
physical health problems in the 30 days prior to treatment. Individuals who identified as transgender had no
detectable differences in emergency room (ER) visits, overnight stays for medical conditions, outpatient
emergency mental health care, or psychiatric hospitalizations in the 30 days prior to treatment. Transgender
men and women were more likely to report having been prescribed medication for mental health in the
previous 30 days and having been diagnosed with a mental illness.

3.5. Substance use behaviors

Transgender status was not predictive of the age the individual first used the primary drug they were seeking
treatment for in men (transgender M = 15.68, SD = 11.67 versus cisgender M = 18.96, SD = 9.24; B = − .283,
semi-partial R2 < .001, p = .812) nor in women (transgender M = 19.47, SD = 9.93 versus
cisgender M = 17.84, SD = 9.84; B = .795, semi-partial R2 < .001, p = .261). When considering primary substance
of abuse, transgender status did not predict higher odds of a specific primary substance of abuse for men, but
among women, transgender status predicted primary methamphetamine use. Neither transgender men(X2 [1] =
0.28, p = .598) nor transgender women (X2 [1] = 0.00, p = .984) were more or less likely than their cisgender
counterparts to report having used their primary substance in the 30 days prior to treatment. Among individuals
who had used their primary substance in the month prior to treatment, transgender status did not predict the
number of days of use among men (M = 13.03, SD = 11.52 for transgender men, M = 16.09, SD = 11.50 for
cisgender men, B = − 2.957, semi-partial R2 < .001, p = .129), nor among women (M = 13.94, SD = 11.71 for
transgender women, M = 16.95, SD = 11.69 for cisgender women, B = − 2.747, semi-partial R2 = .002, p = .038).

4. Discussion
This study identified several unique characteristics of transgender individuals entering substance abuse
treatment. To our knowledge, this is the first large-scale study to examine differences between transgender and
cisgender individuals who are entering substance abuse treatment. Previous studies of individuals entering
substance abuse treatment that have included transgender persons had too small of a transgender sample to
detect differences based on transgender status (as in Cochran & Cauce, 2006) or had to drop transgender
individuals from analyses (as in Cochran et al., 2008), and the epidemiological research has not historically
documented gender identity.

4.1. Demographics

Consistent with previous research (i.e., Clements-Nolle, Marx, Guzman, & Katz, 2001), individuals who identified
as transgender had variable responses to reported sex and to sexual orientation. First, within the transgender
groups, more individuals identified their sex as “other.” It is important for substance abuse treatment providers
and researchers to be careful not to provide labels for individuals wherein none fit. For example, these
participants were asked to endorse either a male to female or female to male category. It is possible that these
two categories do not align with the preferred gender identities of these individuals. Some individuals who do
not identify with their sex assigned at birth may have “declined to answer” the question about gender identity
due to the limited options available. Allowing for a non-binary response option for gender identity can result in a
wealth of responses (see Harrison, Grant, Herman, Dodge, & Imse, 2011 for a discussion), which may be more
accurate to the individual.
Transgender men presenting for substance abuse treatment were considerably younger to a degree that is likely
to be of clinical significance (mid-20s for transgender men versus mid 30s for transgender women and cisgender
individuals). It is possible that this was a cohort trend within the San Francisco area, meaning that there were
more young transgender men in this geographical area at this time, that transgender men were experiencing an
earlier onset of substance abuse problems, or that this particular cohort was willing to identify as transgender at
a younger age. Alternatively, this finding may suggest a willingness to seek treatment earlier. Previous research
has noted a relationship between age seeking treatment and number of previous treatment episodes, with
fewer episodes being associated with a younger age (Cacciola, Dugosh, & Camilleri, 2009), thus this could
represent a treatment group that is more successful in an earlier episode and thus does not return to treatment
for additional episodes.

4.2. Psychosocial considerations related to treatment

Transgender men evidenced strengths that may impact treatment: they were more likely to have recent paid
employment and less likely to have ongoing legal issues. When considered with the younger treatment seeking
age, it is possible that transgender men are entering treatment with more resources likely to support successful
treatment. The finding that transgender men were less likely to have ongoing legal issues may have important
implications for treatment. This suggests that transgender men may be more likely to enter treatment with a
“clean slate” and less likely to have to deal with the repercussions of drug related charges during and after
treatment, or of the ongoing stress associated with being on parole or probation.
Transgender men were, however, more than 5 times as likely as cisgender men to have been living with a
substance abuser. This implyies that transgender men may require additional support while in outpatient
treatment, or when leaving residential treatment, as previous research has suggested poorer treatment
outcomes for individuals in a cohabitating relationship with a substance abuser (Fals-Stewart, Birchler, &
O'Farrell, 1999). Transgender individuals may also be more reliant than cisgender individuals on communities
that are non-family, as they have been shown to experience their families of origin as less supportive (Factor &
Rothblum, 2008) and experience high rates of rejection from families (Grant et al., 2011), thus the power of nonbirth family relationships should be considered in treatment settings. Consistent with this finding, transgender
men reported higher levels of family conflict than did cisgender individuals, however this effect was not
observed in transgender women. Some of this effect could be related to the higher incidence of living with a
substance user, as the term “family” within this question was not defined. Notably, despite previous research
citing higher levels of employment related discrimination for transgender individuals (Herbst et al., 2008), within
a substance abuse treatment setting, transgender women living in San Francisco did not appear to differ from
cisgender women on paid days of work just prior to entering treatment, and transgender men fared better than
cisgender men.

4.3. Health risk behaviors

Consistent with previous research (Edwards, Fisher, & Reynolds, 2007), transgender women reported higher
rates of needle use in the past year. Despite higher levels of needle use within the last year, transgender women
were not more likely to report injection use of the primary substance for which they were seeking treatment.
This points to the possibility that needle use may be involved in administration of medications, such as
hormones, which is consistent with previous research reporting higher rates of injection of hormones than
street drugs (Herbst et al., 2008). Future research is needed to elucidate the needle use practices of transgender
women and identify the specific substances for which needles are used and/or shared. Transgender women
were also more likely to have been tested for HIV. Collectively, these findings suggest that while transgender
women are engaging in higher rates of needle use, they may be more likely to engage in proactive health
behaviors (e.g., HIV testing). Future targeted research is necessary to clarify this relationship.

4.4. Medical and mental health status and service utilization

Greater reports of physical health problems among both transgender women and men indicate that transgender
individuals entering substance abuse treatment may have unique healthcare needs that need to be addressed.
One potential pathway to increased health problems among this community could be the experience of minority
stress. Additional research to elucidate the role of minority stress in health outcomes for transgender individuals
is warranted.
It is difficult to interpret the finding that transgender men and women have higher rates of mental health
diagnoses and use of psychiatric medications, as it is not possible (within this dataset) to identify whether these
diagnoses are for Gender Identity Disorder (as defined by the Diagnostic and Statistical Manual of Mental
Disorders: DSM-IV-TR, American Psychiatric Association, 2000) or a different mental health disorder. Such
findings may be directly related to transgender status, and not other psychiatric conditions. As such, these
results should be interpreted with caution. That being said, existing research with transgender individuals does
suggest that psychological distress is predictive of nonmedical use of prescription medication, which is in turn
associated with illicit drug use (Benotsch et al., 2013). Overall, the findings of increased physical health
problems, mental health diagnoses, and mental health medications indicate that substance abuse programs
need to be prepared to link transgender clients to care for both physical and mental health.

4.5. Substance use behaviors

Transgender women were more than 6 times as likely to be seeking treatment for methamphetamine use, but
aside from that there were no differences in the primary substance for which transgender and cisgender men
and women were seeking treatment. Increased treatment seeking for methamphetamine use may indicate a
greater need for methamphetamine prevention among transgender women. Previous research has found an
association between stimulant use and substance use in the context of sexual activity among transgender
women (Sevelius, Reznick, Hart, & Schwarcz, 2009). Treatment providers for transgender women should assess
for and potentially address the relationship between sexual activity and methamphetamine use among this
population.

4.6. Limitations

This study took place in the urban area of San Francisco, and thus the results reported here are not necessarily
generalizable to other areas of the country. San Francisco is known to be more embracing of diverse gender
identities than many areas of the country (evidenced by structural components such as several transgender
specific health clinics and organizations) and thus represents an atypical environment for transgender
individuals. It is possible that effects due to minority stress would likely be lessened in this geographic area, but
this hypothesis would require additional confirmatory research. This study is also limited by self-report

measures and by utilizing records obtained in a large county health data management system. As such, the data
collection process was at times inconsistent (e.g., annual updates of admissions data were not performed
consistently). Despite these limitations, there is no expectation that self-report or data errors would vary by
gender identity, thus any effects (over-reporting or under-reporting) are likely to be equally distributed within
the sample and not to differ systematically by gender identity. It is also important to note that this is a
treatment-seeking sample, which is not generalizable to all individuals with substance abuse problems. Finally,
the measure of gender identity only allowed two response options for transgender individuals: FTM and MTF.
Additional response options likely would have yielded more individuals who may have identified as transgender.
The reporting of gender identity may be impacted by the modality in which it is collected (e.g., self-report versus
computer assisted interview). While researchers have began to discuss ways to measure gender identity in
health settings (Cahill & Makadon, 2014), more research is needed on the measurement of gender identity.

4.7. Future directions

This study identified multiple differences between transgender and cisgender persons in basic demographics,
psychosocial characteristics, health risk behaviors, health and mental healthcare utilization, and substance use
behaviors. Despite the evidence that points to minority stress processes among the transgender community,
there may also be sources of resilience among transgender people and minority communities, such as
“community cohesiveness” (Meyer, 2003, p. 677), which may reduce minority stressors. This suggests that while
transgender individuals may experience increased stress, they may also have unique sources of strength and
resilience. This study provided an initial foundation to elucidate potential strengths within this community, while
identifying important avenues for future research.
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The term “transgender” can have multiple meanings; it is commonly used to describe people who express their
gender in ways that are incongruent with their biological sex and/or society's dichotomous, male-orfemale conceptualization of gender.

1

